BMS-911543

BMS-911543 is an orally available small molecule inhibitor that selectively targets Janus kinase 2 (JAK2). By inhibiting JAK2 activity, it blocks the JAK/STAT signaling cascade—including activation of STAT3 and STAT5—which can lead to reduced tumor cell proliferation and increased apoptosis. The drug was developed by Bristol Myers Squibb primarily for the treatment of myelofibrosis and other cancers characterized by constitutive JAK2 activation. Preclinical studies demonstrated potent antiproliferative effects in cell lines with mutated or upregulated JAK2 as well as in primary cells from patients with myeloproliferative neoplasms. Clinical development reached phase I/II trials for myelofibrosis but was discontinued before approval[1][2][4][6][7].

Other names

N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo(4,5-d)pyrrolo(2,3b)pyridine-7-carboxamideUNII-7N03P021J8UNII7N03P021J8UNII 7N03P021J8